Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons
- 17 April 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 87 (3) , E281-E288
Abstract
Immune checkpoint inhibitors enhance immune recognition of tumors by interfering with the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed death 1 (PD1) pathways. In the past decade, these agents brought significant improvements to the prognostic outlook of patients with metastatic cancers. Recent data from retrospective analyses and a few prospective studies suggest that checkpoint inhibitors have activity against brain metastases from melanoma and nonsmall cell lung cancer, as single agents or in combination with radiotherapy. Some studies reported intracranial response rates that were comparable with systemic ones. In this review, we provide a comprehensive summary of clinical data supporting the use of anti-CTLA4 and anti-PD1 agents in brain metastases. We also touch upon specific considerations on the assessment of intracranial responses in patients and immunotherapy-specific toxicities. We conclude that a subset of patients with brain metastases benefit from the addition of checkpoint inhibitors to standard of care therapeutic modalities, including radiotherapy and surgery.Keywords
This publication has 68 references indexed in Scilit:
- Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined TreatmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case seriesNeurosurgical Focus, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Risk Factors for Radiation Necrosis After Radiosurgery for Brain MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survivalJournal of Neurosurgery, 2012
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Epidemiology of Brain MetastasesCurrent Oncology Reports, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996